Table 2.
Basic characteristics of the included studies
| Study | Country | Patients (n) | Methods | Primary aim | Methylation site | RUNX3expression |
|---|---|---|---|---|---|---|
| Yu et al27 | People’s Republic of China | 58 | MSP | Determine methylation status of the RUNX3 gene and correlate results with clinicopathological characteristics | Promoter, CpG islands | − |
| Omar et al28 | Singapore | 9 | MSP | Determine frequency of RUNX3 promoter hypermethylation | Promoter, CpG islands | + |
| Tang et al29 | People’s Republic of China | 80 | MSP | Determine methylation status of the RUNX3 gene and correlate results with clinicopathological characteristics | Promoter, CpG islands | − |
| Yanagawa et al30 | Japan | 62 | MSP | Determine methylation status of ten tumor suppressors in NSCLC | Promoter, CpG islands | − |
| Castro et al31 | Spain | 54 | MS-MLPA | Determine clinical significance of several tumor suppressors in NSCLC | Promoter, CpG islands | − |
| Yoshino et al32 | Japan | 44 | MSP | Determine methylation status of 14 tumor suppressors in NSCLC | Promoter, CpG islands | − |
| Yanagawa et al33 | Japan | 101 | MSP | Determine whether methylation status of several genes is correlated with clinicopathological features | Promoter, CpG islands | − |
| Sato et al34 | Japan | 120 | MSP, RT-PCR | Determine role of RUNX3 in pathogenesis of NSCLC | Promoter, CpG islands | + |
| Suzuki et al35 | Japan | 117 | MSP | Determine role of TGF-β-related genes in many human malignancies | Promoter, CpG islands | − |
| Li et al36 | South Korea | 25 | MSP, RT-PCR | Determine role of RUNX3 in pathogenesis of NSCLC | Promoter, CpG islands | + |
| Yanagawa et al37 | Japan | 75 | MSP | Analysis of clinicopathological significance of gene promoter methylation in NSCLC | Promoter, CpG islands | − |
| Hawes et al38 | USA | 117 | MethyLight | Detection of methylation profiles for 27 genes in NSCLC | Promoter, CpG islands | − |
| Feng et al39 | USA | 49 | MethyLight | Analyze DNA methylation status of several genes in NSCLC patients | Promoter, CpG islands | − |
Abbreviations: NSCLC, non-small cell lung cancer; MS-MLPA, methylation-specific multiplex ligation-dependent probe amplification; MSP, methylation-specific polymerase chain reaction; TGF-β, transforming growth factor-beta; RT-PCR, reverse transcription polymerase chain reaction; +, positive; −, negative.